About: Ginkgolic acid inhibits fusion of enveloped viruses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ginkgolic acid inhibits fusion of enveloped viruses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Ginkgolic acid inhibits fusion of enveloped viruses
Creator	Al-Harthi, Lena Bhutta, Maimoona Borenstein, Ronen Cohen, Fredric Gallo, Elisa Hanson, Barbara Lurain, Nell Markosyan, Ruben Narasipura, Srinivas Nicholson, Daniel Shechter, Oren
source	Medline; PMC
abstract	Ginkgolic acids (GA) are alkylphenol constituents of the leaves and fruits of Ginkgo biloba. GA has shown pleiotropic effects in vitro, including: antitumor effects through inhibition of lipogenesis; decreased expression of invasion associated proteins through AMPK activation; and potential rescue of amyloid-β (Aβ) induced synaptic impairment. GA was also reported to have activity against Escherichia coli and Staphylococcus aureus. Several mechanisms for this activity have been suggested including: SUMOylation inhibition; blocking formation of the E1-SUMO intermediate; inhibition of fatty acid synthase; non-specific SIRT inhibition; and activation of protein phosphatase type-2C. Here we report that GA inhibits Herpes simplex virus type 1 (HSV-1) by inhibition of both fusion and viral protein synthesis. Additionally, we report that GA inhibits human cytomegalovirus (HCMV) genome replication and Zika virus (ZIKV) infection of normal human astrocytes (NHA). We show a broad spectrum of fusion inhibition by GA of all three classes of fusion proteins including HIV, Ebola virus (EBOV), influenza A virus (IAV) and Epstein Barr virus (EBV). In addition, we show inhibition of a non-enveloped adenovirus. Our experiments suggest that GA inhibits virion entry by blocking the initial fusion event. Data showing inhibition of HSV-1 and CMV replication, when GA is administered post-infection, suggest a possible secondary mechanism targeting protein and DNA synthesis. Thus, in light of the strong effect of GA on viral infection, even after the infection begins, it may potentially be used to treat acute infections (e.g. Coronavirus, EBOV, ZIKV, IAV and measles), and also topically for the successful treatment of active lesions (e.g. HSV-1, HSV-2 and varicella-zoster virus (VZV)).
has issue date	2020-03-16(xsd:dateTime)
bibo:doi	10.1038/s41598-020-61700-0
bibo:pmid	32179788
has license	cc-by
sha1sum (hex)	7eacd1839afa5931b0b506ae156bbbcecc08b5d0
schema:url	https://doi.org/10.1038/s41598-020-61700-0
resource representing a document's title	Ginkgolic acid inhibits fusion of enveloped viruses
has PubMed Central identifier	PMC7075884
has PubMed identifier	32179788
schema:publication	Sci Rep
resource representing a document's body	covid:7eacd1839afa5931b0b506ae156bbbcecc08b5d0#body_text
is schema:about of	named entity 'IAV' named entity 'Thus' named entity 'CMV' named entity 'acute' named entity 'VZV' named entity 'HSV-2' named entity 'LESIONS' named entity 'PROTEIN ' named entity 'STRONG' named entity 'ACUTE INFECTIONS' named entity 'VIRION' named entity 'MECHANISM' named entity 'SUCCESSFUL TREATMENT' covid:arg/7eacd1839afa5931b0b506ae156bbbcecc08b5d0 named entity 'fusion' named entity 'initial' named entity 'mechanism' named entity 'HSV-1' named entity 'treat' named entity 'experiments' named entity 'successful' named entity 'infection' named entity 'HSV-1' named entity 'successful treatment' named entity 'ZIKV' named entity 'Coronavirus' named entity 'varicella-zoster virus' named entity 'enveloped viruses' named entity 'protein' named entity 'VZV' named entity 'HCMV' named entity 'flavivirus' named entity 'Integrated DNA Technologies' named entity 'screw-capped' named entity 'HSV-1' named entity 'infection' named entity 'Vero cells' named entity 'Sigma Aldrich' named entity 'Class III' named entity '300 nM' named entity 'electrophoretically' named entity 'Viral infection' named entity 'cell fusion' named entity 'FBS' named entity 'mutagenicity' named entity '37 °C' named entity 'cytopathic effect' named entity 'plaque assay' named entity 'FBS' named entity 'ZIKV' named entity 'HSV-1' named entity 'HSV-1' named entity 'bacterial infections' named entity 'polyacrylamide gels' named entity 'ganciclovir' named entity 'MOI' named entity 'HCMV' named entity 'Infection' named entity 'DMEM' named entity 'MOI' named entity 'HCMV' named entity 'protein synthesis' named entity 'Giemsa stain' named entity 'HCMV' named entity 'STAT3' named entity 'cytotoxicity' named entity 'primers' named entity 'FBS' named entity 'FBS' named entity 'Vero' named entity 'HSV-1'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software